102 related articles for article (PubMed ID: 12403050)
1. Validation of microdialysis sampling for oral availability studies by means of a new ganciclovir prodrug.
Lindén K; Zhou XX; Ståble L
Pharmacol Toxicol; 2002 Jun; 90(6):297-302. PubMed ID: 12403050
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
3. Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis.
Macha S; Duvvuri S; Mitra AK
Curr Eye Res; 2004 Feb; 28(2):77-84. PubMed ID: 14972713
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.
Jung D; Dorr A
J Clin Pharmacol; 1999 Aug; 39(8):800-4. PubMed ID: 10434231
[TBL] [Abstract][Full Text] [Related]
5. Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis.
Macha S; Mitra AK
Drug Metab Dispos; 2002 Jun; 30(6):670-5. PubMed ID: 12019194
[TBL] [Abstract][Full Text] [Related]
6. L-valine ester of cyclopropavir: a new antiviral prodrug.
Wu Z; Drach JC; Prichard MN; Yanachkova M; Yanachkov I; Bowlin TL; Zemlicka J
Antivir Chem Chemother; 2009 Sep; 20(1):37-46. PubMed ID: 19794230
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of 2-amino-9-(1, 3-dihydroxy-2-propoxymethyl)- 6-fluoropurine mono- and diesters as potential prodrugs of ganciclovir.
Kim DK; Chang K; Im GJ; Kim HT; Lee N; Kim KH
J Med Chem; 1999 Jan; 42(2):324-8. PubMed ID: 9925738
[TBL] [Abstract][Full Text] [Related]
8. Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats.
Anderson BD; Morgan ME; Singhal D
Pharm Res; 1995 Aug; 12(8):1126-33. PubMed ID: 7494823
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and pharmacokinetics of a double prodrug of ganciclovir in the rat and monkey.
Krasny HC; Beauchamp L; Krenitsky TA; de Miranda P
Drug Metab Dispos; 1995 Nov; 23(11):1242-7. PubMed ID: 8591725
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic studies and LC-MS/MS method development of ganciclovir and dipeptide monoester prodrugs in Sprague Dawley rats.
Gunda S; Earla R; Cholkar K; Mitra AK
Eur J Drug Metab Pharmacokinet; 2015 Sep; 40(3):325-34. PubMed ID: 24943988
[TBL] [Abstract][Full Text] [Related]
12. Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study.
Mouly S; Aymard G; Tillement JP; Caulin C; Bergmann JF; Urien S
Br J Clin Pharmacol; 2001 Jun; 51(6):557-65. PubMed ID: 11422015
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats.
Chae KA; Cho HJ; Sung JM; Lee H; Seo DC; Kim JS; Shin HC
J Vet Sci; 2007 Sep; 8(3):263-7. PubMed ID: 17679773
[TBL] [Abstract][Full Text] [Related]
15. Vitreal pharmacokinetics of peptide-transporter-targeted prodrugs of ganciclovir in conscious animals.
Janoria KG; Boddu SH; Natesan S; Mitra AK
J Ocul Pharmacol Ther; 2010 Jun; 26(3):265-71. PubMed ID: 20565313
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.
Cheng L; Hostetler KY; Lee J; Koh HJ; Beadle JR; Bessho K; Toyoguchi M; Aldern K; Bovet JM; Freeman WR
Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4138-44. PubMed ID: 15505067
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis.
Snell GI; Kotsimbos TC; Levvey BJ; Skiba M; Rutherford DM; Kong DC; Williams TJ; Krum H
J Antimicrob Chemother; 2000 Apr; 45(4):511-6. PubMed ID: 10747829
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the relative bioavailability of oral ganciclovir.
Lavelle J; Follansbee S; Trapnell CB; Buhles WC; Griffy KG; Jung D; Dorr A; Connor J
J Clin Pharmacol; 1996 Mar; 36(3):238-41. PubMed ID: 8690817
[TBL] [Abstract][Full Text] [Related]
19. Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss.
Mouly S; Aymard G; Diquet B; Caulin C; Bergmann JF
J Acquir Immune Defic Syndr; 2000 Aug; 24(4):344-51. PubMed ID: 11015151
[TBL] [Abstract][Full Text] [Related]
20. A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children.
Lukacova V; Goelzer P; Reddy M; Greig G; Reigner B; Parrott N
AAPS J; 2016 Nov; 18(6):1453-1463. PubMed ID: 27450227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
